Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.13 USD
Change Today 0.00 / 0.00%
Volume 0.0
As of 8:10 PM 03/26/15 All times are local (Market data is delayed by at least 15 minutes).

kalbe farma tbk pt (PTKFF) Snapshot

Open
$0.13
Previous Close
$0.13
Day High
$0.13
Day Low
$0.13
52 Week High
07/8/14 - $0.14
52 Week Low
05/29/14 - $0.12
Market Cap
6.1B
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
46.9B
EX-Date
06/16/14
P/E TM
--
Dividend
$18.63
Dividend Yield
1.11%
Current Stock Chart for KALBE FARMA TBK PT (PTKFF)

Related News

No related news articles were found.

kalbe farma tbk pt (PTKFF) Related Businessweek News

No Related Businessweek News Found

kalbe farma tbk pt (PTKFF) Details

PT Kalbe Farma Tbk., together with its subsidiaries, develops, manufactures, and trades pharmaceutical products in Indonesia. It operates in four segments: Prescription Pharmaceuticals, Consumer Health, Nutritionals, and Distribution and Logistics. The company offers generic, branded, and licensed drugs, including Brainact, Cefspan, Mycoral, Cernevit, Cravit, Neuralgin, Broadced, Neurotam, and CPG that are distributed to hospitals, pharmacies, and drug stores. It also provides over-the-counter drugs, energy drinks, ready-to-drink healthy beverage products, supplements, and other preventive products; nutritional products comprising powdered milk products for infants, toddlers, children, pre-teenagers, adults, pregnant and lactating women, and elders, as well as for consumers with special medical needs; and non-milk nutritional products. In addition, the company provides health facilities consisting of clinics, pharmacies, and mini markets, as well as hemodialisis treatments; contract services and resources, including clinical study management, bioavailability/bioequivalence studies, and contract analysis to pharmaceutical companies; and animal health products. Further, it offers health screening services; distributes consumer products, medical equipment, cosmetics, and other trading products; markets and distributes opthalmic products; and trades in medical and laboratory equipment and supplies, raw materials for pharmaceutical products, and consumable products for hemodialysis therapy, as well as provides advertising services. The company was founded in 1966 and is headquartered in Jakarta, Indonesia.

12,084 Employees
Last Reported Date: 03/30/15
Founded in 1966

kalbe farma tbk pt (PTKFF) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

kalbe farma tbk pt (PTKFF) Key Developments

PT Kalbe Farma Tbk Presents at Indonesia Corporate day, Apr-21-2015

PT Kalbe Farma Tbk Presents at Indonesia Corporate day, Apr-21-2015 . Venue: Mandarin Oriental Hotel, Hong Kong.

Kalbe Farma Reports Earnings Result for the Year 2014; Provides Financial Guidance for the Year 2015

Kalbe Farma reported earnings result for the year 2014. The company met its own previously lowered year-end forecast with a 8.5% rise year on year in net sales to IDR 17.4 trillion compared with IDR 16.0 trillion year earlier, on stable growth in its internal products. Operating profit grew 8% year on year to IDR 2.8 trillion, with the operating profit margin remaining at 15.9%, despite the average depreciation of the rupiah by approximately 12.5% in 2014. Net income grew 6.9% year on year to IDR 2.1 trillion. For 2015, Kalbe set a growth target for sales of 11-13% and a target operating profit margin of 16.0-17.0%. The company has also set aside a capital expenditure budget of IDR 1.0-1.3 trillion, most of which will be used to expand manufacturing capacity.

PT Kalbe Farma Tbk to Report Fiscal Year 2014 Final Results on Mar 31, 2015

PT Kalbe Farma Tbk announced that they will report fiscal year 2014 final results on Mar 31, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PTKFF:US $0.13 USD 0.00

PTKFF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PTKFF.
View Industry Companies
 

Industry Analysis

PTKFF

Industry Average

Valuation PTKFF Industry Range
Price/Earnings 41.5x
Price/Sales 4.9x
Price/Book 9.1x
Price/Cash Flow 41.5x
TEV/Sales 4.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KALBE FARMA TBK PT, please visit www.kalbe.co.id. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.